上皮样胶质母细胞瘤与间变性多形性黄色星形细胞瘤中EZH2表达、BRAF V600E突变及CDKN2A/B缺失的评估
该研究评估了15例间变性多形性黄色星形细胞瘤(APXA)和13例上皮样胶质母细胞瘤(EGBM)中EZH2表达、BRAF V600E突变及CDKN2A/B缺失。结果显示EZH2表达随肿瘤级别升高,EGBM中EZH2过表达占69.2%(9/13),APXA占20%(3/15);CDKN2A纯合缺失在EGBM为72.7%(8/11),APXA为12.5%(1/8);BRAF V600E突变在EGBM为80%(8/10),APXA为42.9%(3/7)。单因素分析表明丰富上皮样细胞、广泛坏死、EZH2过表达和BRAF V600E突变与总生存期缩短显著相关(P < 0.05)。
要点
- EZH2过表达在EGBM中占69.2%(9/13),APXA中占20%(3/15)。
- CDKN2A纯合缺失在EGBM中占72.7%(8/11),APXA中占12.5%(1/8)。
- BRAF V600E突变在EGBM中占80%(8/10),APXA中占42.9%(3/7)。
核心结论
- 检测EZH2表达和BRAF V600E突变可能有助于评估EGBM和APXA患者的预后。
- 双相EGBM中异质性EZH2表达可能促进恶性进展。
研究设计与样本
- 评估了15例APXA和13例EGBM病例中EZH2状态、BRAF V600E突变及CDKN2A/B缺失。
主要发现
- EZH2表达水平随肿瘤级别升高。
- EGBM中EZH2过表达占69.2%(9/13),APXA占20%(3/15)。
- 基于荧光原位杂交,EGBM中CDKN2A纯合缺失占72.7%(8/11),APXA占12.5%(1/8)。
- BRAF V600E突变在EGBM中占80%(8/10),APXA中占42.9%(3/7)。
- 在伴有低级别胶质瘤样病变的EGBM中,强EZH2表达和高Ki-67指数仅见于上皮样细胞,低级别病变中未见。
关键数值与推荐
- 单因素分析显示丰富上皮样细胞、广泛坏死、EZH2过表达和BRAF V600E突变与EGBM和APXA患者总生存期缩短显著相关(P < 0.05)。
临床怎么用
- 对EGBM和APXA患者可考虑检测EZH2表达和BRAF V600E突变以辅助预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Epithelioid glioblastoma (EGBM) and anaplastic pleomorphic xanthoastrocytoma (APXA) are two rare entities with different prognoses. However, they share certain morphological and molecular features. MATERIALS AND METHODS: To better recognize EGBM and APXA and identify the prognostic factors associated with these tumors, EZH2 status, BRAF V600E mutations, and CDKN2A/B deletions were assessed in 15 APXA and 13 EGBM cases. RESULTS: The expression level of EZH2 was found to increase with tumor grade. Overexpression of EZH2 occurred in 69.2% (9/13) of EGBM cases and 20% (3/15) of APXA cases. In addition, 72.7% (8/11) of EGBM and 12.5% (1/8) of APXA cases harbored a CDKN2A homozygous deletion based on fluorescence in situ hybridization. BRAF V600E mutations were detected in 80% (8/10) of EGBM cases and 42.9% (3/7) of APXA cases. Furthermore, EGBM, which exhibited co-existing low-grade glioma-like lesions, was found to have strong EZH2 expression and high Ki-67 indexes only in epithelioid cells and not in low grade lesions. Univariate analysis demonstrated that abundant epithelioid cells, extensive necrosis, EZH2 overexpression and BRAF V600E mutations were significantly associated with decreased overall survival in EGBM and APXA patients (P < 0.05). CONCLUSIONS: The results suggested that testing for EZH2 expression and BRAF V600E mutations might be helpful to evaluate the prognoses of EGBM and APXA patients. The presence of heterogeneous EZH2 expression in biphasic EGBMs could also contribute to malignant progression.
引用
- Wang J, Liu Z, Cui Y, et al. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma. J Neurooncol. 2019. PMID: 31214915. doi:10.1007/s11060-019-03212-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。